$74.74
LL-37
What is LL-37?
LL-37 Structure

Research Applications:
Research Links:
-
Dürr, U. H., et al. (2006). “LL-37, the only human member of the cathelicidin family of antimicrobial peptides.” Biochimica et Biophysica Acta (BBA) – Biomembranes, 1758(9), 1408-1425. https://pubmed.ncbi.nlm.nih.gov/16716248/
-
Reviews LL-37’s antimicrobial and immunomodulatory roles, relevant to health and tissue repair.
-
-
Heilborn, J. D., et al. (2003). “The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium.” Journal of Investigative Dermatology, 120(3), 379-389. https://pubmed.ncbi.nlm.nih.gov/12603850/
-
Investigates LL-37’s role in wound healing, applicable to muscle recovery research.
-
-
Ramos, R., et al. (2011). “Wound healing activity of the human antimicrobial peptide LL-37.” Peptides, 32(7), 1469-1476. https://pubmed.ncbi.nlm.nih.gov/21693124/
-
Examines LL-37’s effects on tissue repair and regeneration, supporting muscle recovery studies.
-
-
Scott, M. G., et al. (2002). “The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses.” Journal of Immunology, 169(7), 3883-3891. https://pubmed.ncbi.nlm.nih.gov/12244192/
-
Explores LL-37’s immunomodulatory effects, relevant to health and inflammation control.
-
-
Shaykhiev, R., et al. (2014). “Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure.” American Journal of Physiology – Lung Cellular and Molecular Physiology, 287(6), L1157-L1163. https://pubmed.ncbi.nlm.nih.gov/15347564/
-
Studies LL-37’s role in cell proliferation and tissue repair, with implications for muscle recovery.
-
Product Note:
For laboratory use only. Not for human or veterinary use. Proper handling and storage (-20°C) are required to maintain stability. Ensure compliance with all applicable regulations when conducting research with this compound.
| Size |
4mg |
|---|
